Spotlight
Clinical
Events
CME
Partners
Subscribe
- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
CIBA Vision sells Epi-LASIK technology to Australian firm
Atlanta-An Australian medical device company will take over the Epi-LASIK surgical product line as part of CIBA Vision's divestiture of its surgical business (also see Page 1). Norwood Abbey Ltd., Melbourne, Australia, bought the Centurion SES system and EpiEdge epikeratome separator for $10 million. The company paid $1 million when it signed the agreement in May, and it signed a note with CIBA Vision for $9 million for the balance of the technology and inventory price.
Related Content
